Core Viewpoint - The company, Guoshentang (02273.HK), anticipates significant revenue and profit growth for the first half of 2025 compared to the same period in 2024, driven by increased patient visits and business expansion efforts [1][2] Financial Projections - The company expects to achieve revenue between RMB 1,474 million and RMB 1,529 million in the first half of 2025, representing an increase of approximately 8% to 12% compared to RMB 1,365 million for the first half of 2024 [1] - The projected net profit for the first half of 2025 is estimated to be between RMB 149 million and RMB 155 million, reflecting a growth of approximately 39% to 44% from RMB 107.3 million in the first half of 2024 [1] - Adjusted net profit is expected to be between RMB 167 million and RMB 175 million, which is an increase of approximately 13% to 18% compared to RMB 147.9 million in the first half of 2024 [1] Business Drivers - The increase in revenue, net profit, and adjusted net profit is primarily attributed to a rise in patient visits at the company's medical institutions, which is a result of the company's ongoing efforts to provide comprehensive and high-quality traditional Chinese medical health services, enhancing the recognition of the "Guoshentang" brand [2] - The company's business expansion, including an increase in the number of physicians and the growth of medical institutions and geographical coverage, has also contributed to the positive financial outlook [2]

本公告乃由固生堂控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體 統稱為「本集團」）根據香港法例第571章證券及期貨條例第XIVA部項下內幕消 息條文（定義見香港聯合交易所有限公司證券上市規則（「上市規則」））及上市 規則第13.09(2)(a)條而刊發。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東（「股東」）及本公司潛 在投資者，根據目前可獲得的資料及對本集團截至2025年6月30日止六個月 （「2025年上半年」）未經審核綜合管理賬目的初步審閱，預期本集團將(a)於2025 年上半年錄得收入約人民幣1,474百萬元至人民幣1,529百萬元，相比截至2024 年6月30日止六個月（「2024年上半年」）的收入人民幣1,365.0百萬元增加約8%至 12%；(b)於2025年上半年錄得溢利淨額約人民幣149百萬元至人民幣155百萬元， 相 比2024年上半年的溢利淨額人民幣107.3百萬元增加約39%至44%； 及(c)於 2025年上半年錄得經調整溢利淨額人民幣167百萬元至人民幣175百萬元，相比 2024年上半年的經調整溢利淨額人民幣147.9百萬元增加約13%至18%。 – 1 – ...

Core Viewpoint - UBS initiates coverage on Guosheng Tang (02273) with a "Buy" rating and a target price of HKD 48.30, corresponding to 20x/17x projected P/E ratios for 2025/2026 and a PEG of 0.9 for 2026 [1] Company Summary - Guosheng Tang is positioned as a leading player in the healthcare services sector due to its strong growth prospects and low valuation [1] - The company has established a sustainable and rewarding career development platform for traditional Chinese medicine practitioners, presenting significant opportunities for increasing practitioner coverage and productivity [1] - Guosheng Tang is expanding its self-paid value-added services to mitigate policy risks, leveraging its advantages in the Chinese medicine supply chain, talent resources, and technology [1] Industry Summary - The report highlights potential catalysts for Guosheng Tang, including sustained strong profit growth, rapid clinic expansion, and advancements in in-hospital formulations, artificial intelligence technology, and overseas expansion [1] - The company is well-positioned to benefit from the long-term opportunities arising from the reform of payment methods such as DRG/DIP, which may incentivize higher-tier public hospitals to refer chronic disease patients downwards [1] - Guosheng Tang is expected to maintain a 20% adjusted profit CAGR from 2024 to 2027, with strong visibility in growth, compared to the Visible Alpha consensus expectation of 19% [1]

智通财经APP获悉，瑞银发布研报称，首次覆盖固生堂(02273)给予买入评级和目标价48.30港元，对应 20倍/17倍2025 年/2026年预测市盈率/经调整盈利，以及0.9倍2026年预测市盈增长比率 (PEG)。考虑到 其强劲的增长前景和较低的估值，固生堂是该行在医疗健康服务领域的首选标的。潜在的催化剂包括： 持续强劲的盈利增长、诊所快速扩张，以及在院内制剂、人工智能技术和海外扩张方面的进展。 报告指，固生堂为中医师建立了一个可持续且回报丰厚的职业发展平台，在增加医师覆盖率和提升其生 产力方面存在显著机遇。除了在中医药供应链、人才资源和技术方面的优势，固生堂还在拓展其自费增 值业务以应对政策风险。长期来看，该行认为在 DRG/DIP 等支付方式改革后，高层级公立医院可能被 激励将慢性病患者向下转诊。固生堂凭借其专注于慢性病、贴近城市社区以及差异化和高质量的产品/ 服务，定位良好，有望从中受益，在承接公立医院慢性病患者方面的长期机遇。该行预测固生堂在 2024-2027 年期间能够维持20%的经调整盈利复合年增长率 (CAGR)(Visible Alpha 共识预期为 19%)，增 长可见性强。 ...

Core Viewpoint - UBS has initiated a "Buy" rating for Guoshengtang with a target price of HKD 48.3, forecasting a compound annual growth rate (CAGR) of 20% for adjusted earnings from 2024 to 2027 [1] Summary by Relevant Categories Company Growth Potential - UBS believes that investors may underestimate Guoshengtang's advantages in attracting doctors, managing policy risks, and serving chronic disease patients from public hospitals [1] - The company's sustainable growth is supported by its expertise in traditional Chinese medicine and value-added services [1] Market Opportunities - There are favorable opportunities for Guoshengtang to enhance doctor coverage and productivity [1] - The company is expanding its self-paid value-added services by leveraging its strengths in the traditional Chinese medicine supply chain, talent, and technology to mitigate policy risks [1]

Core Viewpoint - UBS initiates coverage on Guoshengtang (2273.HK) with a "Buy" rating and a target price of HKD 48.3, corresponding to a 17x projected P/E ratio for 2026 [1] Group 1: Financial Projections - UBS forecasts a compound annual growth rate (CAGR) of 20% for adjusted earnings from 2024 to 2027, surpassing the market average expectation of 19% [1] - The firm highlights strong visibility in Guoshengtang's growth prospects, supported by favorable valuation and limited policy risks [1] Group 2: Competitive Advantages - Guoshengtang's ability to attract and retain doctors is emphasized as a significant advantage, along with its capacity to manage policy risks and long-term opportunities from public hospitals treating chronic disease patients [1] - The company is building a sustainable and rewarding career development platform for traditional Chinese medicine, which is expected to enhance doctor coverage and productivity [1] Group 3: Market Opportunities - UBS notes that Guoshengtang is actively expanding its self-paid value-added services to mitigate policy risks, leveraging its strengths in the traditional Chinese medicine supply chain, talent resources, and technology [1] - Long-term, Guoshengtang is positioned to benefit from the trend of public hospitals referring chronic disease patients downwards, aided by its focus on chronic diseases and proximity to urban communities [1]

2025开年以来港股市场表现活跃，主要指数涨势喜人。公募机构对港股的关注度显著提升，不仅主 动权益类基金、QDII基金积极布局港股，一些"固收+"基金也大举配置港股，向港股市场要收益。数据 显示，多只"固收+"基金对港股的持仓接近了合同规定的港股投资比例上限，得益于"纯债资产打底""港 股红利防御"和"科技龙头增厚"的三重配置优势，这些"固收+"基金近期普遍取得了不错的业绩。 "固收+"产品含"港"量提升 2025开年以来，港股市场表现亮眼。Wind数据显示，截至3月20日，恒生指数和恒生科技指数年内 涨幅分别超过20%和30%。 港股市场的潜在上行空间吸引了主动权益类基金和QDII基金的关注，截至去年底，在港交所挂牌 的腾讯控股成为公募基金第二大重仓股，小米集团、中芯国际等港股标的也成为公募基金增持较多的品 种；QDII基金也日益展现出配置重点转向港股的趋势。 "固收+"基金同样也在投资范围内积极配置港股。数据显示，截至去年底，全市场二级债基合计持 有的港股市值达到54.2亿元。从基金管理人来看，二级债基港股持仓市值最高的是广发基金，旗下相关 产品合计持有港股市值达7.89亿元。 从单只基金来看，7只二级债 ...

Investment Rating - The report maintains a positive investment outlook on innovative drugs and medical devices, highlighting them as key investment themes in the current market environment [2][4][43]. Core Insights - The report emphasizes the ongoing support from the government for innovative medical drugs and devices, particularly in the brain-computer interface (BCI) sector, which is expected to see significant advancements by 2027 and 2030 [1][51]. - The innovative drug sector remains a primary investment focus, with a recommendation to pay attention to leading pharmaceutical companies' transformation results and their opportunities for international expansion [2][43]. - The report identifies a growing interest in innovative medical devices, driven by favorable policies and a recovery in medical equipment procurement trends, suggesting a potential performance turnaround in the second half of the year [4][12]. Summary by Sections Innovative Drugs - The innovative drug sector is highlighted as a key investment line, with a focus on potential blockbuster drugs and collaborations for innovative drug development [2][43]. - The report notes that after multiple rounds of generic drug procurement, risks for leading pharmaceutical companies are gradually being alleviated, revealing competitive innovative drug pipelines [2][43]. Biological Products - Anke Biotech's subsidiary has received approval for a shingles mRNA vaccine, indicating progress in the mRNA drug development space [2][45]. - The report suggests continued monitoring of Anke Biotech's collaboration with its subsidiary and the advancements in mRNA drug development [2][50]. Medical Devices - The report discusses the government's support for the BCI industry, which is expected to accelerate commercialization and product development [1][3]. - It highlights the recovery trend in medical device procurement and the increasing market share of leading companies, indicating a strong performance outlook for the sector [4][12]. Traditional Chinese Medicine - Some traditional Chinese medicine companies are in a good cash flow position and are expected to see growth through innovative product pipelines and strategic investments [3][19]. Medical Services and Consumer Healthcare - The report notes a series of positive earnings announcements from high-growth stocks in the medical services sector, indicating a robust growth outlook [3][4].

金融界8月5日消息，上证指数高开高走，中证港股通医疗商业与服务综合指数 (港股通医疗商业， 931966)报1701.32点。 数据统计显示，中证港股通医疗商业与服务综合指数近一个月上涨10.64%，近三个月上涨12.75%，年 至今上涨22.94%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证港股通综合指数调整样本时，样本随之进行 相应调整。若中证港股通综合指数样本有特殊事件发生，导致其行业归属发生变化，指数样本进行相应 调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆、停牌等情形的处理， 参照计算与维护细则处理。 本文源自：金融界 作者：行情君 从指数持仓来看，中证港股通医疗商业与服务综合指数十大权重分别为：京东健康（16.57%）、阿里 健康（14.32%）、国药控股（13.85%）、平安好医生（11.27%）、上海医药（6.64%）、医脉通 （6.0%）、锦欣生殖（5.1%）、海吉亚医疗 ...

Core Viewpoint - Morgan Stanley's research report indicates that China Resources Medical has issued a profit warning for the first half of this year, with net profit attributable to ordinary shareholders expected to decline by 20% to 25% year-on-year [1] Financial Performance - Excluding a compensation of 210 million yuan related to the YanHua IOT agreement, the underlying business profit is projected to decline by 55% to 60% year-on-year, which is below market consensus and Morgan Stanley's estimates [1] - Morgan Stanley sets a target price of 3 HKD for China Resources Medical and maintains a "Reduce" rating [1] Industry Impact - The company attributes the profit decline to a reduction in average medical insurance reimbursement per visit, indicating increased reimbursement pressure across regions due to DRG/DIP 2.0 [1] - This situation is expected to negatively impact other hospital operators that rely on public insurance, such as Haijia Medical, Gushengtang, Jinxin Fertility, and Aier Eye Hospital [1]